StockTake: Neurizon’s lead asset shows positive results in latest study

In a big step forward in the development of NUZ-001, Neurizon teams up with Tessara for further testing on its lead candidate.

Neurizon Therapeutics' (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with Tessara Therapeutics.

NUZ-001 has shown it promotes healthy and viable brain tissues, potentially demonstrating its use to provide short-term treatment for further neurodegenerative diseases. 

Watch the video to hear more.

This video was developed in collaboration with Neurizon Therapeutics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as StockTake: Neurizon’s lead asset shows positive results in latest study